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Background
Although tumour-specific cytotoxic T cells are capable of
killing tumour cells both in vitro and in vivo, treatment
with adoptive T cell transfer does not lead to sufficient
tumour regression without adjuvant therapy. Tumour-
promoted T cell exhaustion and anergy have been pro-
posed to contribute to this lack of efficacy. We and
others have previously shown that programmed death
receptor-1 (PD-1) upregulation is a hallmark of tumour
infiltrating, adoptively transferred T cells. PD-1 and its
ligand (PD-L1) constitute a major immunosuppressive
axis driven by tumour cells. Disruption of this axis may
hit an Achilles heel of tumour immune escape.
Material and methods
A PD1-CD28 chimeric receptor was cloned into the ret-
roviral vector pMP71 and expressed in primary murine
T cells specific for the model antigen ovalbumin (OT-1
cells). Functionality was addressed in vitro using ELISA
and flow cytometry. In vivo, ovalbumin and PD-L1 over-
expressing Panc02 cells (syngeneic pancreatic cancer cell
line) were inoculated subcutaneously in immunocompe-
tent female C57Bl/6 mice. Mice (n = 6 per group) were
treated twice i.v. with PD1-CD28 chimeric receptor-
transduced T cells or control T cells.
Results
In vitro, PD-1-CD28 chimeric receptor-transduced pri-
mary T cells released 130 fold more interleukin-2 (IL-2)
and 300 fold more interferon-g than untransduced or
control-transduced T cells when stimulated with CD3
and PD-L1, demonstrating the functionality of the chi-
meric receptor (p = 0.0014). In co-culture experiments
with the Panc02 tumour cells, effective co-stimulation
through PD1-CD28 was only seen in the presence of the
TCR-recognized antigen ovalbumine and PD-L1. Upon
blockade of MHC or PD-1, co-stimulation through the
receptor was abrogated. Culture of transduced T cells in
the presence of CD3 and PD-L1 increased cell numbers 4
fold and significantly increased viability of cells compared
to untransduced or control-transduced T cells (p <
0.0001). In vivo, treatment of mice with an established
(OVA and PD-L1 expressing) Panc02 subcutaneous
tumour (mean tumour size at treatment onset 26 mm2)
with PD1-CD28-transduced OT-1 slowed tumour growth
compared to treatment with control-transduced OT-1
cells (p < 0.001). This demonstrates the functionality of
the chimeric receptor in an immunocompetent organism.
Conclusions
Adoptive T cells therapy with PD-1-CD28 chimeric
receptor-transduced T cells is a promising approach to
overcome PD-1-PD-L1-mediated tumour-induced
anergy and immunosuppression.
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